Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5938 USD | -4.99% | +2.40% | -27.74% |
May. 30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
May. 13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 21.61M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.13% |
1 day | -4.99% | ||
1 week | +2.40% | ||
1 month | -11.51% | ||
3 months | -17.94% | ||
6 months | +19.24% | ||
Current year | -27.74% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Wagner
CEO | Chief Executive Officer | 53 | 16-12-31 |
Anthony Riley
DFI | Director of Finance/CFO | 57 | 20-02-29 |
Chief Operating Officer | - | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Gryska
BRD | Director/Board Member | 68 | 23-01-09 |
Steven Kornfeld
BRD | Director/Board Member | 56 | 20-05-31 |
Director/Board Member | 65 | 22-05-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.5938 | -4.99% | 9,172 |
24-05-30 | 0.625 | +2.46% | 89,314 |
24-05-29 | 0.61 | -6.30% | 82,043 |
24-05-28 | 0.651 | +12.26% | 65,506 |
24-05-24 | 0.5799 | -3.35% | 10,053 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.74% | 21.61M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- FBRX Stock